Results 11 to 20 of about 820 (140)

Emicizumab Associated Rhabdomyolysis in Hemophilia A [PDF]

Clinical Hematology International, 2020
Emicizumab is increasingly the front-line treatment for patients with Hemophilia A with or without inhibitors. Rhabdomyolysis is a syndrome of muscle necrosis and release of intracellular muscle constituents into the circulation. Creatine kinase (CK) levels are typically markedly elevated, and muscle pain and myoglobinuria may be present.
Joseph A. Wilson, Stephanie Hayden, Alexander Asamoah, Vivek R. Sharma, David C. Jennings, Ashok B. Raj   +5 more
openaire   +5 more sources

Evaluation of Safety and Efficacy of Emicizumab Prophylaxis in Egyptian Pediatric Patients with Hemophilia A

Turkish Journal of Hematology
Objective: Hemophilia A (HA) is a hereditary X-linked bleeding disorder secondary to deficiency of the clotting factor VIII (FVIII). Emicizumab is a monoclonal antibody that replaces the function of the activated FVIII and prevents bleeding in HA ...
Tamer Hassan, Marwa Zakaria, Manar Fathy, Ahmed Farag, Eman Abdelhady, Dalia Gameil, Mustafa Abu Hashem   +6 more
doaj   +2 more sources

Laboratory Assessment of Emicizumab Levels in Hemophilia A: Influence of Assay Selection on Reported Results

Clinical and Applied Thrombosis/Hemostasis
Background Emicizumab has emerged as a promising therapy for hemophilia A (HA), employing a bypassing mechanism to restore hemostasis. However, since the traditional factor assays cannot be used for measuring the effect of emicizumab, treatment ...
Charlotte Gran MD, PhD, Tony Frisk MD, PhD, Margareta Homström MD, PhD, Maria Magnusson MD, PhD, Susanna Ranta MD, PhD, Anna Sjöström MD, PhD, Marjan Shafaati Lambert, Nida Mahmoud Hourani Soutari BSc, Jovan P. Antovic MD, PhD, Roza Chaireti MD, PhD   +9 more
doaj   +2 more sources

Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review

Clinical and Applied Thrombosis/Hemostasis
Background Emicizumab, a bispecific factor VIII mimetic antibody, was approved in 2018 for bleeding prophylaxis in congenital hemophilia A with or without inhibitors.
Ghachem Ikbel MD, Baccouche Hela MD, Kaabar Mohamed Yassine MD, Khemiri Hamida MD, Ben Salem Kamel MD   +4 more
doaj   +2 more sources

Modelling US health equity impacts of emicizumab for severe haemophilia A: aggregate distributional cost-effectiveness analysis

BMJ Open
Objectives Emicizumab is the first bispecific antibody approved for prophylaxis in people with haemophilia A with or without factor VIII inhibitors. Aggregate distributional cost-effectiveness analysis assesses health equity impacts by evaluating how ...
Randall Curtis, Thomas Majda, Janet S. Lee, Stacey L. Kowal   +3 more
doaj   +2 more sources

Importance of Inhibitor Surveillance During Emicizumab Prophylaxis in Young Children With Hemophilia: An Illustrative Case Series

Case Reports in Hematology
Hemophilia is an X-linked inherited bleeding disorder associated with bleeding, which starts in infancy. The age of initiation of prophylaxis with clotting factor concentrate is limited by the intravenous mode of administration. Emicizumab, a Factor VIII
Kelly A. Bush, Marc Durocher, Jacqueline Limjoco, Courtney D. Thornburg   +3 more
doaj   +2 more sources

Emicizumab, the factor VIII mimetic bispecific monoclonal antibody: effects on thrombin generation and thromboelastometry

Research and Practice in Thrombosis and Haemostasis
Background: Emicizumab is used for prophylaxis of patients with hemophilia A. Because it is used at a fixed dose that is not based on laboratory testing, evaluation of its activity is occasionally needed.
Armando Tripodi, Marigrazia Clerici, Erica Scalambrino, Sara Arcudi, Roberta Gualtierotti, Cristina Novembrino, Flora Peyvandi   +6 more
doaj   +2 more sources

Thrombin generation to predict breakthrough bleeding in patients with acquired hemophilia A under emicizumab prophylaxis

Haematologica
Acquired hemophilia A (AHA) is a serious bleeding disorder due to neutralizing autoantibodies against factor VIII (FVIII). Emicizumab mimics the activity of FVIIIa restoring thrombin generation.
Fabius J. Pelzer, Ella I. Ertekin, Olga Oleshko, Annika Klingberg, Paul Knöbl, Christian Pfrepper, Richard Greil, Johannes Oldenburg, Ulrich J. Sachs, Wolfgang Miesbach, Karolin Trautmann-Grill, Katharina Holstein, Hermann Eichler, Patrick Möhnle, Christina Hart, Robert Klamroth, Andreas Tiede, Sonja Werwitzke   +17 more
doaj   +3 more sources

Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres [PDF]

, 2023
INTRODUCTION Haemophilia A care has changed with the introduction of emicizumab. Experience on the youngest children is still scarce and clinical practice varies between haemophilia treatment centres.
Jan Blatny, Ranta, Susanna, Nadine G. Andersson, Kathelijn Fischer, Martina Bührlen, Christoph Male, Escuriola, Carmen, Gili Kenet, d'Oiron, Roseline, Ester Zapotocka, Blatny, Jan, Kenet, Gili, Motwani, Jayashree, Königs, Christoph, Mutlu Kartal‐Kaess, Andersson, Nadine G., Carcao, Manuel, Marloes de Kovel, Roseline d'Oiron, de Kovel, Marloes, Kartal-Kaess, Mutlu, Andersson, Nadine, Martin Olivieri, Carmen Escuriola, Zapotocka, Ester, Jayashree Motwani, Male, Christoph, Christoph Königs, Manuel Carcao, Susanna Ranta, Bührlen, Martina, Andersson, Nadine G, Nolan, Beatrice, Olivieri, Martin, Chambost, Hervé, Fischer, Kathelijn, Beatrice Nolan, Hervé Chambost   +37 more
core   +3 more sources

Effect of emicizumab-neutralizing antibodies on activated partial thromboplastin time–based clotting time test results in patients treated with emicizumab [PDF]

, 2023
Background: Emicizumab is a bispecific humanized monoclonal antibody that shortens the activated partial thromboplastin time (aPTT), making aPTT-based tests unreliable.
Novembrino, Cristina, Peyvandi, Flora, Boscolo-Anzoletti, Massimo, Shinohara, Sho, Galbiati, Eleonora   +4 more
core   +1 more source